Hims & Hers 股价因可能销售某些未经批准的肽类产品而上涨

路透中文
Oct 29
BUZZ-Hims & Hers 股价因可能销售某些未经批准的肽类产品而上涨

10月28日 - ** Hims & Hers Health(HIMS.N)股价上涨5%,至29.35美元,此前美国卫生部门表示将暂时允许 (link) 销售部分未经批准的肽类产品

** 远程医疗公司HIMS表示,若法规允许,该公司计划提供肽类产品

** 该临时政策涵盖六种肽类物质,包括广受欢迎的组织修复化合物BPC-157,监管机构正在就正式允许将其用于复方制剂一事作出决定

** Leerink分析师迈克尔·切尔尼表示,此举理论上至少将这些肽类药物的市场机遇提前了数月

** 但他同时提醒:“该通知距离HIMS为决定充分利用这一机遇所需要的‘绿灯’仍相去甚远”

** 该股年初至今累计下跌10.6%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10